How ultra-fast FLASH radiation may spare healthy tissue during cancer treatment
Using experimentally-guided multi-scale modeling to determining the mechanism of FLASH tissue sparing
Researchers are finding out if ultra-fast FLASH radiation can protect normal tissues while treating cancers such as bone metastases and brain tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11141656 on NIH RePORTER |
What this research studies
From a patient's perspective, the team combines lab experiments in animal tissues with detailed computer simulations to understand what causes the FLASH sparing effect. They model oxygen changes and radiochemistry using tools developed by the group and compare those models to experimental results in intestine, brain and skin. The work is experimentally guided and uses multi-scale simulations to define safe dose, dose rate, and timing needed for tissue protection. The goal is to turn these findings into clearer plans for clinical trials and safer FLASH treatments for people with tumors like bone metastases or brain lesions.
Who could benefit from this research
Good fit: People with cancers treated by radiation—especially those with symptomatic bone metastases or brain tumors—would be the most likely candidates for related clinical trials or future FLASH treatments.
Not a fit: Patients whose cancers are not treated with radiation or who are ineligible for experimental radiotherapy approaches would not expect direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could reduce radiation damage to healthy tissue and lower side effects for patients receiving radiotherapy.
How similar studies have performed: Animal studies have repeatedly shown FLASH tissue sparing and a few early human cases and initial proton FLASH trials have been reported, but the mechanism and optimal clinical settings remain unproven.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Schuemann, Jan Patrick Oscar — Massachusetts General Hospital
- Study coordinator: Schuemann, Jan Patrick Oscar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.